Search

Researchers from UC San Diego, the J. Craig Venter Institute and Yale University have been awarded $10 million by the Howard Hughes Medical Institute (HHMI) to support research on using jumbo viruses as new therapeutic agents.

In this new paper in Frontiers in Microbiology, Qin Qi (Macquarie University, Australia) and colleagues present evidence that temperate and virulent (lytic) bacteriophages (phages) carry integrons. Integrons are mobile genetic elements that

In a new paper in PNAS, Benoit Pons (University of Exeter) and colleagues show that antibiotics that target the protein translation machinery can alter the outcome of bacteria-phage interactions by interfering with the production of phage-e

A new paper by Jan Finke (Hakai Institute, Canada) and colleagues describes Deep6, a deep learning model for classification of metatranscriptomic sequences into prokaryotes, eukaryotes, or one of the four viral realms (Duplodnaviria, Varidn

Daniela Rothschild-Rodriguez and colleagues published a new paper exploring the role of phages in influencing the mucosal integrity of the human gut, and how these interactions may affect health and disease states. They also cover phage-enc

Research Scientist at A&P Inphatec in Palo Alto, CA A&P Inphatec, LLC has commercialized the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source o

Research Scientist at A&P Inphatec in Palo Alto, CA A&P Inphatec, LLC has commercialized the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source o

Research Scientist at A&P Inphatec in Palo Alto, CA A&P Inphatec, LLC has commercialized the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source o

Research Scientist at A&P Inphatec in Palo Alto, CA A&P Inphatec, LLC has commercialized the first product to treat Pierce’s Disease in grapevines. Our unique solution utilizes bacteriophages to target and kill the bacteria at the source o

This week, Dr. Josh Jones from UK Phage Therapy drops an announcement on the establishment of a new UK-based phage therapy screening and manufacturing initiative, which will function as the UK’s national clinical phage centre. Bacteriophage

The Gao Lab at Stanford University is seeking a postdoctoral scientist in structural biology to join their new research team. The lab is focused on exploring and harnessing the vast diversity of genes throughout Earth’s microbiome to unders

The Ohio State University is looking for a postdoctoral scholar to help coordinate datasets and associated laboratory activities for both microbial and phage banks. The scholar's technical expertise will support the research and development

Postdoctoral position: computational biology of temperate phage host range in Klebsiella at Jagiellonian University, Mostowy Lab in Krakow, Poland We are seeking a motivated and driven person to do a post-doc in the group of Rafal Mostowy

The University of Exeter is offering a funded PhD studentship on 'Multi-layered bacterial genome defences: linking molecular mechanisms to bacteria-MGE conflicts in single cells, populations, and communities'.

In the latest episode of the Phage Therapy Today podcast, Carrie-Lynn Langlais Furr, CEO and Co-founder at Bacteriophage & Drug Development Consultants (BDDC) talks about how to navigate the drug development and regulatory waters for phage

The next Viruses of Microbes conference will be held in Tbilisi, Georgia on July 3-7, 2023. The conference marks a new era in viral research which has begun with the recognition of viruses of microorganisms – viruses of bacteria, archaea, a

In this PBS Vitals video, Alok Patel (MD) and Sheena Williams (RN) explore how phage therapy could help humanity win the battle against antibiotic-resistant superbugs.

Vésale Bioscience, a Belgian phage therapy company, has been awarded a €1.8m grant from the European Innovation Council to develop a phage therapy diagnostic platform to fight multidrug-resistant infections.

Adaptive Phage Therapeutics announced that the first patient has been dosed in the PHAGE clinical trial, evaluating bacteriophage therapy in adults with cystic fibrosis who carry Pseudomonas aeruginosa in their lungs.

Ben Chan (Center for Phage Biology & Therapy, Yale University) and colleagues report the use of a personalized, inhaled phage therapy for treating P. aeruginosa infections in 9 CF adults, with the goal of selecting phages that target bacter